FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 429 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... July 21, 2023 Coronavirus reports – Part 7: “I’m more concerned about the second... November 24, 2020 Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for... May 19, 2026 FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma August 14, 2025 Load more HOT NEWS Cancer, COVID-19, and Competing Threats to Indigenous Health Do Black Lives Matter Less Than Those of Cancer Survivors? How to Provide Support as a Long-Distance Cancer Caregiver New ESMO President 2029-2030 Elected
